Sign up to access all valuation multiples
The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The Company has one operating business segment; The Franchise Operations segment which is comprised of the operating activities of the franchise business unit. The Franchise Operations segment derives revenue from customers by providing access to the Company’s franchise license, which represents symbolic intellectual property.
2010
736
LTM Revenue $54.1M
LTM EBITDA $11.2M
$113M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
As of September 2025, Joint reported last 12-month revenue of $54.1M and EBITDA of $11.2M.
In the same period, Joint generated $42.6M in LTM gross profit and -$1.9M in net income.
See Joint valuation multiples based on analyst estimatesIn the most recent fiscal year, Joint reported revenue of $51.9M and EBITDA of $3.0M.
Joint expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Joint valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $54.1M | XXX | $51.9M | XXX | XXX | XXX |
| Gross Profit | $42.6M | XXX | $40.4M | XXX | XXX | XXX |
| Gross Margin | 79% | XXX | 78% | XXX | XXX | XXX |
| EBITDA | $11.2M | XXX | $3.0M | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 6% | XXX | XXX | XXX |
| EBIT | -$0.5M | XXX | -$1.7M | XXX | XXX | XXX |
| EBIT Margin | -1% | XXX | -3% | XXX | XXX | XXX |
| Net Profit | -$1.9M | XXX | -$8.5M | XXX | XXX | XXX |
| Net Margin | -4% | XXX | -16% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Joint has current market cap of $141M, and EV of $113M.
As of October 2, 2025, Joint's stock price is $9.
See Joint trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $113M | $141M | XXX | XXX | XXX | XXX | $-0.14 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialJoint's trades at 2.2x EV/Revenue multiple, and 38.0x EV/EBITDA.
See valuation multiples for Joint and 15K+ public compsAs of October 2, 2025, Joint has market cap of $141M and EV of $113M.
Equity research analysts estimate Joint's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Joint has a P/E ratio of -74.1x.
| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $141M | XXX | $141M | XXX | XXX | XXX |
| EV (current) | $113M | XXX | $113M | XXX | XXX | XXX |
| EV/Revenue | 2.1x | XXX | 2.2x | XXX | XXX | XXX |
| EV/EBITDA | 10.1x | XXX | 38.0x | XXX | XXX | XXX |
| EV/EBIT | -231.4x | XXX | -65.0x | XXX | XXX | XXX |
| EV/Gross Profit | 2.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | -74.1x | XXX | -16.5x | XXX | XXX | XXX |
| EV/FCF | 118.4x | XXX | 13.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialJoint's last 12 month revenue growth is 9%
Joint's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Joint's rule of 40 is 17% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Joint's rule of X is 44% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Joint and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | 8% | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 6% | XXX | XXX | XXX |
| EBITDA Growth | 12% | XXX | 10% | XXX | XXX | XXX |
| Rule of 40 | 17% | XXX | 15% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 44% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 21% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 81% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| National Healthcare Corp | XXX | XXX | XXX | XXX | XXX | XXX |
| Eureka Group Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| Propel Funeral Partners | XXX | XXX | XXX | XXX | XXX | XXX |
| Regis Healthcare | XXX | XXX | XXX | XXX | XXX | XXX |
| Maternus-Kliniken | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Joint acquired XXX companies to date.
Last acquisition by Joint was XXXXXXXX, XXXXX XXXXX XXXXXX . Joint acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Joint founded? | Joint was founded in 2010. |
| Where is Joint headquartered? | Joint is headquartered in United States of America. |
| How many employees does Joint have? | As of today, Joint has 736 employees. |
| Who is the CEO of Joint? | Joint's CEO is Mr. Sanjiv Kumar Razdan. |
| Is Joint publicy listed? | Yes, Joint is a public company listed on NAS. |
| What is the stock symbol of Joint? | Joint trades under JYNT ticker. |
| When did Joint go public? | Joint went public in 2014. |
| Who are competitors of Joint? | Similar companies to Joint include e.g. National Healthcare Corp, Eureka Group Holdings, Propel Funeral Partners, Regis Healthcare. |
| What is the current market cap of Joint? | Joint's current market cap is $141M |
| What is the current revenue of Joint? | Joint's last 12 months revenue is $54.1M. |
| What is the current revenue growth of Joint? | Joint revenue growth (NTM/LTM) is 9%. |
| What is the current EV/Revenue multiple of Joint? | Current revenue multiple of Joint is 2.1x. |
| Is Joint profitable? | Yes, Joint is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Joint? | Joint's last 12 months EBITDA is $11.2M. |
| What is Joint's EBITDA margin? | Joint's last 12 months EBITDA margin is 21%. |
| What is the current EV/EBITDA multiple of Joint? | Current EBITDA multiple of Joint is 10.1x. |
| What is the current FCF of Joint? | Joint's last 12 months FCF is $1.0M. |
| What is Joint's FCF margin? | Joint's last 12 months FCF margin is 2%. |
| What is the current EV/FCF multiple of Joint? | Current FCF multiple of Joint is 118.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
